4-Oct-2024
No headlines found.
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 30-Sep 5:08 PM ET)
Business Wire (Mon, 30-Sep 4:30 PM ET)
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
Business Wire (Mon, 30-Sep 7:00 AM ET)
Business Wire (Thu, 19-Sep 7:00 AM ET)
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Business Wire (Tue, 27-Aug 4:00 PM ET)
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
Business Wire (Mon, 19-Aug 7:00 AM ET)
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
Business Wire (Tue, 13-Aug 7:00 AM ET)
Adicet Bio to Participate in Upcoming Investor Conferences
Business Wire (Thu, 1-Aug 4:00 PM ET)
Business Wire (Mon, 8-Jul 7:00 AM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of October 4, 2024, ACET stock price was flat at $1.42 with 121,228 million shares trading.
ACET has a beta of 1.46, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.04 to the broad based SPY ETF.
ACET has a market cap of $117.01 million. This is considered a Micro Cap stock.
Last quarter Adicet Bio reported $0 in Revenue and -$.33 earnings per share. This fell short of revenue expectation by $-620,000 and exceeded earnings estimates by $.03.
In the last 3 years, ACET traded as high as $21.87 and as low as $1.05.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, FESM, IWC, CNCR.
ACET has underperformed the market in the last year with a price return of +10.1% while the SPY ETF gained +36.6%. However, in the short term, ACET had mixed performance relative to the market. It has outperformed in the last 3 months, returning +30.3% vs +4.2% return in SPY. But in the last 2 weeks, ACET shares have been beat by the market, returning -7.2% compared to an SPY return of +0.8%.
ACET support price is $1.35 and resistance is $1.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.